Last reviewed · How we verify
MT-2990
At a glance
| Generic name | MT-2990 |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Exploratory Study of MT-2990 in Patients With AAV (PHASE1)
- Safety and Efficacy Study of MT-2990 in Women With Endometriosis (PHASE2)
- A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients (PHASE1)
- A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-2990 CI brief — competitive landscape report
- MT-2990 updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI